EP0423266A1 - Method and composition for treatment of periodontal disease - Google Patents

Method and composition for treatment of periodontal disease

Info

Publication number
EP0423266A1
EP0423266A1 EP90905014A EP90905014A EP0423266A1 EP 0423266 A1 EP0423266 A1 EP 0423266A1 EP 90905014 A EP90905014 A EP 90905014A EP 90905014 A EP90905014 A EP 90905014A EP 0423266 A1 EP0423266 A1 EP 0423266A1
Authority
EP
European Patent Office
Prior art keywords
composition
periodontal disease
chlorhexidine gluconate
allantoin
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90905014A
Other languages
German (de)
French (fr)
Other versions
EP0423266A4 (en
Inventor
Marc N Benhuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0423266A1 publication Critical patent/EP0423266A1/en
Publication of EP0423266A4 publication Critical patent/EP0423266A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles

Definitions

  • the present invention relates to a method and composition for treatment of periodontal disease and, more particularly, to a composition suitable for topical application to prevent and treat periodontitis.
  • Periodontal disease is the major cause of tooth loss in adults.
  • the periodontium is subject to inflammation for many reasons, primary among them being the accumulation of plaque deposits under and above the gumline.
  • These calcareous deposits of organic and mineral matter consist of microbial colonies growing in carbohydrate residues (from food) , attach themselves to tooth surfaces and can, over time, calcify into tartar. This hard, mineralized substance adheres tenaciously to the teeth and, when under the gumline, causes inflammation of the periodontium.
  • Other causes of periodontitis can include malocclusion, food impaction and mouth breathing.
  • Periodontitis outside of taking preventive measures to keep it from developing in the first place, was surgery.
  • the accepted surgical procedure involves removing the inflamed gum tissue, which is expensive and requires a long and painful recovery.
  • a composition suitable for treating periodontitis comprises an aqueous solution of an antimicrobial agent with bacteriacidal activity, an agent with therapeutic action against skin ulcers, an analgesic, a stain remover and, if desired, suitable wetting agents, emulsifiers, dispersants, buffers stabilizers, preservatives, flavoring and coloring.
  • the various components of the composition of the present invention are present in an aqueous carrier of sterile distilled water, glycerine and ethanol.
  • the glycerine provides the composition with the desired feel and texture and the ethanol acts as an antiseptic.
  • chlorhexidine gluconate (0.12% solution), C 3 H 5 Cl 2 N 10 O 14 (Merck Index 2057) , as an antimicrobial agent with bacteriacidal action, (2) allantoin, or (2,5-dioxo-4- imidazolidinyl)urea (Merck Index 242) as an agent that exhibits therapeutic action against skin ulcers, (3) sodium salicylate, or 2-hydroxybenzoic acid monosodium salt (Merck Index 8515) , as an analgesic, and (4) sodium bicarbonate (Merck Index 8414) as a stain remover, along with wetting agents, preservatives, emulsifiers, dispersants, buffers stabilizers, flavoring and coloring, as desired. (All references herein to the Merck Index refer to the 1983 edition.)
  • the above ingredients are provided in the following proportions:
  • Ethanol (MI 212) 7.50% Polysorbate 80 (as an emulsifier and dispersant; MI 7455) 4.20% Chlorhexidine gluconate (0.12% sol.) (MI 2057) 3.50% Sodium bicarbonate (as a stain remover; MI 8414) 0.50% Sodium lauryl sulfate (as a wetting agent; MI 8474) 0.50%
  • MI 8413 0.10% Xanthan gum (as a stabilizer and e ulsifier; MI 9868) 0.10%
  • the above composition is prepared by first measuring an appropriate quantity of sterile distilled water; for example, lOOOcc of the composition is to be prepared, 101 . lc . of water are used. The remaining ingredients are added in the order listed in Table 1, with each ingredient being thoroughly mixed by gently stirring the composition before the next ingredient is added.
  • a clinical test involving 30 people was performed using a composition similar to that set out above, except for using 72.77% sterile water, 8.00% ethanol, 1.50% chlorhexidine gluconate (0.12% solution) and 0.138% allantoin.
  • the subjects were chosen because all exhibited, periodontal pockets up to 8mm or 9mm deep.
  • Prior to beginning the treatment regimen all 30 subjects agreed not to brush or floss their teeth for one week.
  • 15 of the subjects rinsed their mouths three times a day with 1.0 cc of the above composition 30 seconds before brushing and 15 rinsed their mouths three times a day with an equal amount of a colored sugar-water placebo 30 seconds before brushing.
  • the subjects did not know whether they were using the inventive composition or the placebo.

Abstract

Une composition de traitement de maladie périodontique comprend un support aqueux d'eau stérile, de glycérine et d'éthanol, dans lequel sont présents gluconate de chlorhexidine, allantoïne, salicylate de sodium et bicarbonate de sodium. Un procédé de traitement préféré consiste en l'application locale au périoste alvéolaire de l'homme dans un bain de bouche.A periodontal disease treatment composition comprises an aqueous carrier of sterile water, glycerin and ethanol, in which are present chlorhexidine gluconate, allantoin, sodium salicylate and sodium bicarbonate. A preferred treatment method consists of local application to the human alveolar periosteum in a mouthwash.

Description

METHOD AND COMPOSITION FOR TREATMENT OF PERIODONTAL DISEASE
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a method and composition for treatment of periodontal disease and, more particularly, to a composition suitable for topical application to prevent and treat periodontitis.
Description of the Prior Art
Periodontal disease is the major cause of tooth loss in adults. The periodontium is subject to inflammation for many reasons, primary among them being the accumulation of plaque deposits under and above the gumline. These calcareous deposits of organic and mineral matter, which consist of microbial colonies growing in carbohydrate residues (from food) , attach themselves to tooth surfaces and can, over time, calcify into tartar. This hard, mineralized substance adheres tenaciously to the teeth and, when under the gumline, causes inflammation of the periodontium. Other causes of periodontitis can include malocclusion, food impaction and mouth breathing.
Periodontitis can cause the gumline to retract due to supporting bone loss and the gums to bleed, and eventually, if not treated, can result in tooth loss. Until now, the only known treatment for periodontitis, outside of taking preventive measures to keep it from developing in the first place, was surgery. The accepted surgical procedure involves removing the inflamed gum tissue, which is expensive and requires a long and painful recovery.
There have been various attempts at treating periodontal disease without such surgical intervention. The best such attempt to date resides in an oral rinse sold by Procter & Gamble under the name Peridex®. The chemistry of this product is described in the 1988 Phvsicans' Desk Reference at pages 1648-49. Unfortunately, Peridex® rinse has not proved as efficacious against periodontal disease as might be desired and exhibits unwanted side effects, such as staining of tooth surfaces.
The following patents also disclose oral treatment agents, but none is believed to represent a substitute for surgical intervention as a treatment for periodontal disease:
Re.31,397 4,213,961
2,684,924 4,332,791
3,887,712 4,339,430
3,925,543 4,454,110
3,937,807 4,486,404
3,957,967 4,569,837
4,051,234 4,601,900
4,067,962 4,661,342 4,198,392
Of interest with regard to the present invention are U.S. Patent 4,486,404 which, in Example 5, discloses a toothpaste containing chlorhexidine gluconate and allantoin, U.S. Patents 3,937,807 and 4,051,234, which disclose mouthwashes with gluconates and anti-stain agents, and U.S. Patent 4,569,837, which discloses the use of chlorhexidine gluconate and aspirin to treat periodontal disease. SUMMARY OF THE INVENTION It is an object of the present invention to provide a composition and method for treating Periodontitis I without costly and painful surgical intervention.
In accordance with one aspect of the invention, a composition suitable for treating periodontitis comprises an aqueous solution of an antimicrobial agent with bacteriacidal activity, an agent with therapeutic action against skin ulcers, an analgesic, a stain remover and, if desired, suitable wetting agents, emulsifiers, dispersants, buffers stabilizers, preservatives, flavoring and coloring.
In accordance with another aspect of the invention, the composition is used in a treatment method which comprises the steps of topically applying the composition to inflamed periodontium.
DESCRIPTION OF PREFERRED EMBODIMENTS In a preferred embodiment of the invention the various components of the composition of the present invention are present in an aqueous carrier of sterile distilled water, glycerine and ethanol. The glycerine provides the composition with the desired feel and texture and the ethanol acts as an antiseptic.
To this water-glycerine-ethanol carrier is added (1) chlorhexidine gluconate (0.12% solution), C3H5Cl2N10O14 (Merck Index 2057) , as an antimicrobial agent with bacteriacidal action, (2) allantoin, or (2,5-dioxo-4- imidazolidinyl)urea (Merck Index 242) as an agent that exhibits therapeutic action against skin ulcers, (3) sodium salicylate, or 2-hydroxybenzoic acid monosodium salt (Merck Index 8515) , as an analgesic, and (4) sodium bicarbonate (Merck Index 8414) as a stain remover, along with wetting agents, preservatives, emulsifiers, dispersants, buffers stabilizers, flavoring and coloring, as desired. (All references herein to the Merck Index refer to the 1983 edition.)
In particularly preferred embodiment, the above ingredients are provided in the following proportions:
TABLE 1
Sterile Water 70.77%
Glycerine (MI 4347) 11.15%
Ethanol (MI 212) 7.50% Polysorbate 80 (as an emulsifier and dispersant; MI 7455) 4.20% Chlorhexidine gluconate (0.12% sol.) (MI 2057) 3.50% Sodium bicarbonate (as a stain remover; MI 8414) 0.50% Sodium lauryl sulfate (as a wetting agent; MI 8474) 0.50%
Vanilla (as flavoring; MI 9732) 0.60%
Saccharine (as flavoring; MI 8170) 0.20%
Sodium salicylate (MI 8515) 0.15%
Allantoin (MI 242) 0.638% Sodium benzoate (as a preservative;
MI 8413) 0.10% Xanthan gum (as a stabilizer and e ulsifier; MI 9868) 0.10%
Sodium borate (as a buffer; MI 8421) 0.085%
F.D.& C. Blue (as coloring) 0.005%
F.D.& C. Red 40 (as coloring) 0.002%
[Notes to Table 1 - (1) All proportions of the above ingredients are v/v; (2) "MI" refers to the Merck Index]
The above composition is prepared by first measuring an appropriate quantity of sterile distilled water; for example, lOOOcc of the composition is to be prepared, 101 . lc . of water are used. The remaining ingredients are added in the order listed in Table 1, with each ingredient being thoroughly mixed by gently stirring the composition before the next ingredient is added.
A clinical test involving 30 people was performed using a composition similar to that set out above, except for using 72.77% sterile water, 8.00% ethanol, 1.50% chlorhexidine gluconate (0.12% solution) and 0.138% allantoin. The subjects were chosen because all exhibited, periodontal pockets up to 8mm or 9mm deep. Prior to beginning the treatment regimen, all 30 subjects agreed not to brush or floss their teeth for one week. Then, 15 of the subjects rinsed their mouths three times a day with 1.0 cc of the above composition 30 seconds before brushing and 15 rinsed their mouths three times a day with an equal amount of a colored sugar-water placebo 30 seconds before brushing. The subjects did not know whether they were using the inventive composition or the placebo.
Once a week the teeth of each subject were checked for the presence of plaque using a commercially available plaque- disclosing solution, Superdent® disclosing solution concentrate, made by Rugby Laboratories, Inc., of Rockville Centre, Long Island, NY 11570. All subjects using the inventive composition showed little or no plaque accumulation, while there was such plaque accumulation on the teeth of the subjects using the placebo.
The test procedures were continued for 12 weeks, and the subjects' conditions were measured in accordance with the Simplified Oral Hygiene Index (OHI-S) described in Orban's Periodontics (3rd Ed. 1968), The C.V. Mosby Co., St. Louis, MO, at page 134. It was found that the average OHI-S for the subjects on the placebo went from 8mm to 9mm periodontal pocket depth to 6mm to 8mm pocket depth during the 12 week test, while that for the subjects using the inventive composition improved from 8mm" to 9mm periodontal pocket depth to 2mm or 3mm pocket depth, which is considered within normal range.
It is expected that repeated use of the inventive solution will reduce inflammation, stop bleeding and keratenize damaged periodontal tissue.
Of course, variations of the above preferred embodiment are possible within the scope of the present invention, such as varying the proportions of the chlorhexidine gluconate, allantoin and sodium salicylate within ranges that provide efficacious results. It is intended by the claims appended below to include all such variations within the present invention.

Claims

WHAT I CLAIM IS :
1. A composition for treating periodontal disease comprising an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate.
2. A composition according to claim 1, further comprising a stain remover.
3. A composition according to claim 2, wherein said stain remover is sodium bicarbonate.
4. A composition according to claim 1, wherein said chlorhexidine gluconate is present as a 0.12% solution and said aqueous carrier consists essentially of sterile water, glycerine and ethanol.
5. A composition for treating periodontal disease consisting essentially of the following ingredients in the following amounts according to volume:
Sterile Water 70.77%
Glycerine 11.15%
Ethanol 7.50%
Polysorbate 80 4.20% Chlorhexidine gluconate (0.12% sol.) 3.50%
Sodium bicarbonate 0.50%
Sodium lauryl sulfate 0.50%
Sodium salicylate 0.15%
Allantoin 0.638% Xanthan gum 0.10%
Preservatives, buffers, flavoring and coloring 0.992%
6. A method for treating periodontal disease comprising the steps of: providing a composition including an aqueous carrier having therein chlorhexidine gluconate, allantoin and sodium salicylate; and applying said composition topically to a human periodontium.
7. A method according to claim 5, wherein the composition further includes a stain remover.
8. A method according to claim 6, wherein the stain remover is sodium bicarbonate.
EP19900905014 1989-02-28 1990-02-28 Method and composition for treatment of periodontal disease Withdrawn EP0423266A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31727189A 1989-02-28 1989-02-28
US317271 1989-02-28

Publications (2)

Publication Number Publication Date
EP0423266A1 true EP0423266A1 (en) 1991-04-24
EP0423266A4 EP0423266A4 (en) 1991-09-25

Family

ID=23232900

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900905014 Withdrawn EP0423266A4 (en) 1989-02-28 1990-02-28 Method and composition for treatment of periodontal disease

Country Status (4)

Country Link
EP (1) EP0423266A4 (en)
AU (1) AU5287090A (en)
CA (1) CA2028136A1 (en)
WO (1) WO1990009779A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1257345B (en) 1992-06-02 1996-01-15 HIGHLY EFFECTIVE SCLEROSANT SOLUTION, WHICH DOES NOT PRODUCE IATROGEN INJURY AND PROCEDURE TO OBTAIN THIS SOLUTION.
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US20020054895A1 (en) 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US6864274B2 (en) 1999-07-23 2005-03-08 Alwyn Company, Inc. Allantoin-containing skin cream
US6896897B2 (en) 1999-07-23 2005-05-24 Alwyn Company, Inc. Flexible applicator for applying oil-in-water emulsion with improved stability
US6329413B1 (en) 1999-07-23 2001-12-11 Alwyn Company, Inc. Allantoin-containing skin cream
US6281236B1 (en) 1999-07-23 2001-08-28 Alwyn Company, Inc. Oil-in-water emulsion with improved stability
US6531500B2 (en) 1999-07-23 2003-03-11 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
US6673826B2 (en) 1999-07-23 2004-01-06 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
ATE444086T1 (en) * 1999-12-07 2009-10-15 Univ Rutgers THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING PERIODONTITIS WITH ANTI-INFLAMMATORY AGENTS
US20040038948A1 (en) 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
BRPI0618475B1 (en) 2005-11-09 2016-10-11 Klox Technologies Inc composition, tooth whitening method and kit
EP2102144A4 (en) 2006-09-13 2011-03-23 Univ Rutgers Active agents and their oligomers and polymers
US20100266989A1 (en) 2006-11-09 2010-10-21 Klox Technologies Inc. Teeth whitening compositions and methods
CN102256591B (en) 2008-11-07 2016-02-10 克洛克斯科技公司 Comprise the Oxidatitive photoactivated skin rejeuvenation composition of hyaluronic acid, glycosamine or allantoin
EP2453922B1 (en) * 2009-07-17 2017-10-25 Klox Technologies Inc. Antibacterial oral composition
US20140135372A1 (en) 2010-02-02 2014-05-15 Elliott Farber Compositions and methods of treatment of inflammatory skin conditions using allantoin
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
US11116841B2 (en) 2012-04-20 2021-09-14 Klox Technologies Inc. Biophotonic compositions, kits and methods
US9144579B2 (en) 2012-08-17 2015-09-29 Rutgers, The State University Of New Jersey Polyesters and methods of use thereof
BR112015005593B1 (en) 2012-09-14 2019-09-24 Valeant Pharmaceuticals International, Inc. Teeth Whitening Method
US20140120057A1 (en) 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US20140276354A1 (en) 2013-03-14 2014-09-18 Klox Technologies Inc. Biophotonic materials and uses thereof
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
US9862672B2 (en) 2013-05-29 2018-01-09 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
EP3016686A4 (en) 2013-07-03 2017-01-25 Klox Technologies Inc. Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds
CN103893026B (en) * 2014-03-31 2018-04-06 陈光健 It is a kind of to be used for oral cleaning and the mouthwash of health care
WO2015149177A1 (en) 2014-04-01 2015-10-08 Klox Technologies Inc. Tissue filler compositions and methods of use
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
WO2016065488A1 (en) 2014-10-31 2016-05-06 Klox Technologies Inc. Photoactivatable fibers and fabric media
JP6930918B6 (en) 2015-04-10 2021-12-15 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー Kojic acid polymer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2529271A1 (en) * 1975-07-01 1977-01-13 Erich Hofacker Treatment and prophylaxis of gum diseases - with compsn. contg. salt of chlorophenyl biguanide deriv. and pref. tetrahydroimidazole deriv.
EP0085891A1 (en) * 1982-01-26 1983-08-17 LABORATORI BALDACCI Spa A composition for the cleaning and hygien of teeth

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370314A (en) * 1975-12-08 1983-01-25 Colgate-Palmolive Company Oral composition containing antibacterial agent
US4454110A (en) * 1982-05-24 1984-06-12 Forsyth Dental Infirmary For Children Self-gelling liquid composition for topical application in the oral cavity
US4512968A (en) * 1982-11-30 1985-04-23 Lion Corporation Oral compositions
JPS59222406A (en) * 1983-06-01 1984-12-14 Teijin Ltd Pharmaceutical preparation for remedying periodontosis and its preparation
AU7204787A (en) * 1986-03-17 1987-10-09 Oral Research Laboratories, Inc. Treatment of dental surfaces with plaque retardants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2529271A1 (en) * 1975-07-01 1977-01-13 Erich Hofacker Treatment and prophylaxis of gum diseases - with compsn. contg. salt of chlorophenyl biguanide deriv. and pref. tetrahydroimidazole deriv.
EP0085891A1 (en) * 1982-01-26 1983-08-17 LABORATORI BALDACCI Spa A composition for the cleaning and hygien of teeth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9009779A1 *

Also Published As

Publication number Publication date
EP0423266A4 (en) 1991-09-25
CA2028136A1 (en) 1990-09-29
WO1990009779A1 (en) 1990-09-07
AU5287090A (en) 1990-09-26

Similar Documents

Publication Publication Date Title
EP0423266A1 (en) Method and composition for treatment of periodontal disease
Ernst et al. The effectiveness and side effects of 0.1% and 0.2% chlorhexidine mouthrinses: a clinical study.
Balagopal et al. Chlorhexidine: the gold standard antiplaque agent
EP0169888B1 (en) Dental rinse
US4097604A (en) Method of treating and controlling gingivitis
US7115252B2 (en) Therapeutic compositions and methods of use thereof
US5236699A (en) Antiplaque mouth rinse
US3651208A (en) Dentifrice for periodontia purposes
Mandel Calculus update: prevalence, pathogenicity and prevention
US4215144A (en) Method of treating and controlling gingivitis
US4839158A (en) Process and composition for oral hygiene
US4214006A (en) Mouthwash and method for preventing and removing dental plaque
JP2981772B2 (en) Dental hygiene composition for reducing periodontal disease
Holbeche et al. A clinical trial of the efficacy of a cetylpyridinium chloride‐based mouth wash*: 1. Effect on plaque accumulation and gingival condition
US6589513B2 (en) Oral hygiene formulation and method of use
US5403579A (en) Process and composition for oral hygiene
US6497858B1 (en) Method of remineralizing teeth
JP2548265B2 (en) Oral hygiene medicine
US6440395B1 (en) Antiplaque mouth rinse
RU2060030C1 (en) Dental paste
Bokor The effect of hexetidine spray on dental plaque following periodontal surgery
CA2481004A1 (en) Novel anti-bacterial compositions
Asrorovna et al. Clinical And Morphological Assessment Of The Effectiveness Of Application Of Anti-Inflammatory Toothpasts In The Complex Treatment Of Periodontal Diseases In Patients With Glucose Exchange
US20070020200A1 (en) Therapeutic compositions and methods of use thereof
Yengopal Essential oils: some lesser known uses and properties for improved oral health

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19901026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910808

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19920331